AI & Diagnostics Software

Mindera Health develops precision medicine diagnostics for dermatological conditions, specifically psoriasis. The company's flagship product, Mind.Px™, is a non-invasive diagnostic patch that captures thousands of RNA transcripts from a penny-sized skin sample in approximately five minutes. The device employs Dermal Intelligence™ technology to enable scalable collection and analysis of individualized genetic information, providing actionable, data-driven treatment guidance for patients, providers, and payers. Mind.Px is designed to support biologic therapy selection for psoriasis patients, reducing trial-and-error treatment approaches. The company markets directly to healthcare providers and patients, offering physician resources, online test ordering, and patient education materials. Mindera Health has received regulatory approval from the New York State Department of Health as of April 2026, enabling national availability across all 50 states. The platform combines genomic RNA analysis with clinical dermatology to support precision treatment decisions. Target users include dermatologists, rheumatologists, and other providers managing psoriasis patients seeking to optimize biologic therapy outcomes.

XRHealth is a digital health company specializing in AI-powered extended reality (XR) therapeutic solutions for clinical and home-based care. The company develops virtual reality and immersive software platforms that deliver evidence-based treatment for pain management, cognitive behavioral therapy, physical rehabilitation, occupational therapy, and mental health interventions. XRHealth's flagship product, the XRHealth VR CBT Device, is Medicare-covered as durable medical equipment (DME) under HCPCS Code E1905. The company also offers the XR CareCart, a plug-and-play VR rehabilitation station for deployment in clinics, hospitals, and community settings. XRHealth 2.0 is described as a unified XR therapeutic ecosystem integrating AI-driven personalization, dynamic avatars, and clinical support tools. The platform supports conditions including anxiety, ADHD, autism spectrum disorder, Parkinson's disease, stroke rehabilitation, cancer-related symptoms, and burn wound management. XRHealth holds FDA registration for its medical devices and has secured patents for XR-based impulsivity measurement systems. The company operates through multiple acquisition-driven product lines (acquired Innerworld, RealizedCare, NeuroReality/Koji's Quest, and merged with Amelia Virtual Care) and positions itself as a B2B provider serving healthcare organizations, clinicians, therapists, and patients. Services include clinical delivery, treatment planning, and clinician AI assistant functionality.

Leica Microsystems, a Danaher company, manufactures and sells optical and digital microscopy solutions for life science research, medical/surgical applications, industrial inspection, forensics, and education. The company serves over 175 years of heritage in revealing microscopic structures through advanced imaging technology. Product portfolio includes light microscopes (inverted and stereo), surgical microscopes for ophthalmology, neurosurgery, ENT, plastic reconstructive surgery, and dentistry. Key products include the DMi8 inverted microscope platform for research workflows, MyVeo all-in-one surgical visualization headset for heads-up OR collaboration, Ivesta 3 Greenough stereo microscopes for industrial inspection, Stellaris confocal microscopes, and Proveo 8x 3D digital surgical microscopes. The company offers sample preparation equipment including the UC Enuity ultramicrotome for electron microscopy. Aivia is their AI-powered 2-to-5D image visualization, analysis, and interpretation platform for complex image processing. ATTO-TEC consumables (fluorescent dyes) serve fluorescence microscopy imaging applications. Leica operates an online shop with pre-configured bundles and provides remote care/predictive service systems. The company maintains global distribution through authorized partners and serves clinical, research, and industrial markets. Regional presence includes Germany (headquarters in Wetzlar) with US operations.

Integrated DNA Technologies (IDT) is a life sciences research reagents and molecular biology tools supplier headquartered in Coralville, Iowa. The company manufactures custom DNA and RNA oligonucleotides, primers, probes, and gene fragments for research applications. IDT's product portfolio includes custom DNA/RNA oligos with rapid turnaround (>90% of standard orders within 24 hours, quality-checked by ESI-MS); Ultramer oligos; oligo pools; SameDay and Rapid HPLC oligo services; modified nucleotides and linkers; qPCR/dPCR probes and assays under the PrimeTime trademark; PCR primers and master mixes; CRISPR-Cas9 and CRISPR-Cas12a systems with guide RNAs, libraries, and enzymes; gene synthesis and gBlocks HiFi gene fragments (NGS-verified); next-generation sequencing (NGS) library preparation kits (DNA, RNA, methyl-seq), hybridization capture panels, amplicon panels, and library normalization tools under the xGen brand; Archer Anchored Multiplex PCR sequencing assays for oncology, infectious disease, and liquid biopsy applications; gene regulation products including RNAi, antisense oligonucleotides, and miRNA inhibitors; GMP oligo and CGMP CRISPR manufacturing for therapeutic development; and OEM services including custom assay development, integrations, APIs, PAGE/HPLC purification, and formulation/packaging. IDT serves academic research, diagnostic development, and therapeutic development markets. The company emphasizes rapid turnaround, quality control, and regulatory compliance in manufacturing.

Kemtai is a FDA-listed, CE-marked, HIPAA- and GDPR-compliant digital physical therapy platform that delivers AI-guided exercise and assessment software for rehabilitation, physical therapy, and wellness programs. The company develops computer vision technology that analyzes 111 body data points to provide real-time corrective feedback during exercises without requiring sensors or wearables. Kemtai serves health systems, hospitals, rehabilitation centers, payers (insurers, HMOs, value-based care organizations), digital health platforms, and medical device manufacturers. The platform includes Kemtai CARE, a standalone clinician app for managing patients, assigning exercise protocols, ROM assessments, and tracking adherence and performance metrics. Core capabilities include a library of 2,000+ exercises and movement variations, automated patient notifications, in-app messaging, and white-label customization. Integration is available via robust API framework for embedding into third-party platforms. Clinical validation demonstrates 72% average patient adherence, 33% reduction in in-person appointments, and 95% patient satisfaction. The technology is designed for at-home guided rehab, pre-operative therapy, post-operative recovery tracking, and chronic condition management across MSK, cardiac, neurological, and obesity care. Processing occurs on-device with no video recording, ensuring maximum privacy compliance.

Phase Scientific International Limited develops proprietary diagnostic technology and rapid testing solutions for early disease detection, with focus on cancer and infectious diseases. The company's core innovation is PHASIFY™, a molecular detection platform that enables faster, easier identification of target biomarkers compared to conventional diagnostics. PHASIFY™ powers three product and service lines: INDICAID® at-home rapid tests for point-of-care use; INDICAID lab™ at-home laboratory testing kits; and PHASE lab, a clinical laboratory service offering cancer and infectious disease testing. Recent product launches include FebriDx®, a respiratory pathogen test awarded FDA CLIA waiver (March 2026), and urine-based HPV screening for cervical cancer detection. The company markets solutions for cancer screening, cervical health monitoring, and respiratory/infectious disease diagnostics. Manufacturing and regulatory capabilities include FDA CLIA certification and active clinical research partnerships. The company has raised $34 million Series A funding and maintains operations in Asia and North America, positioning itself as an innovator in preventive diagnostics and non-invasive biomarker detection.

Forj Medical is a global contract design and manufacturing organization (CDMO) specializing in advanced medical device development and high-volume manufacturing. The company operates 450,000+ square feet of manufacturing space across six global facilities (U.S., Costa Rica, Singapore, Indonesia) and assembles 250+ million devices and components annually. Core competencies include electromagnetic sensors and navigation systems, surgical energy systems, fluid and gas management solutions, optical systems, stimulation and active wearables, and consumables and components. Forj Medical provides end-to-end services from concept and full medical device system development through commercialization, including custom electromechanical system design, design for manufacturing (DFM), design for automation and scale, custom prototyping, and process and test development. Manufacturing capabilities are vertically integrated, encompassing PCBA manufacturing, precision molding, cable assembly, cleanroom operations, polymer and metal 3D printing, and automation. The company maintains ISO 13485 certification and holds five FDA Establishment Registrations. Quality management systems include robust QMS, traceability protocols, risk management, and audit readiness. Supply chain and operational services include supply chain management, service and maintenance, sustaining engineering, packaging and shipping, and international logistics. Clients span Fortune 500 medical device manufacturers and emerging medtech companies. The organization combines 4+ million combined hours of medical device engineering expertise across its portfolio.

RaySearch Laboratories is a Swedish medical software company specializing in oncology treatment planning and management solutions. The company develops advanced software platforms that enable cancer treatment centers to optimize radiation therapy, chemotherapy, and adaptive care workflows. RaySearch's primary offering is RayCare, an integrated oncology information system designed to support thousands of clinics worldwide. The company collaborates with leading cancer centers to translate scientific advancements into clinical solutions. RaySearch operates in the radiation oncology and comprehensive cancer care software space, serving hospitals and specialized cancer treatment facilities globally. The company is publicly traded (AB publ) and maintains active participation in major oncology conferences including ECIO and IBA's International Symposium on Proton Therapy. Recent expansion includes market entry in China with initial RayCare orders.

Sun Nuclear Corporation is a global leader in radiation oncology quality assurance (QA) solutions, serving over 6,000 healthcare facilities in more than 130 countries. Founded in 1984 and headquartered in Melbourne, Florida, the company specializes in comprehensive QA platforms for radiation therapy and diagnostic imaging, with solutions deployed in over 90% of U.S. cancer treatment centers and 60% of global facilities. Sun Nuclear provides advanced dosimetry verification, machine QA, patient-specific plan verification, and AI-powered treatment planning tools. The portfolio includes proprietary detector technologies, phantom systems, and integrated software solutions designed to enhance patient safety and streamline clinical workflows. In 2021, Sun Nuclear was acquired by Mirion Technologies, strengthening its position in radiation safety innovation. The company offers extensive clinical support, training, and service backed by over 300 years of combined team expertise and 34 patents in radiation oncology and diagnostic imaging QA.

Radformation is a healthcare technology company specializing in AI-driven automation software for radiation oncology workflows. Founded in 2016 and based in New York, the company develops intelligent tools that enhance efficiency, reduce errors, and improve cancer treatment planning across oncology clinics. Radformation's integrated platform supports the complete treatment lifecycle—from automated contouring and planning to quality assurance, treatment monitoring, and billing automation. Key offerings include AutoContour (480+ deep-learning anatomical structures), EZFluence (3D automated planning), ClearCheck (plan evaluation), ClearCalc (independent dose calculation), RadMonteCarlo (Monte Carlo calculations), ChartCheck (real-time treatment monitoring), ChartCheck Adaptive (adaptive dose tracking), QuickCode (billing QA), and RadMachine (machine QA). The platform seamlessly integrates with Eclipse™ TPS and supports photon, electron, proton, and brachytherapy modalities. With over 1,400 clinic installations and multiple regulatory clearances, Radformation enables cancer treatment centers to standardize workflows, increase patient throughput, and deliver safer, higher-quality radiation treatments.

BBI Solutions is a UK-based biotechnology company founded in 1986, specializing in high-quality reagents, antibodies, antigens, enzymes, and related services for the diagnostics and life sciences industries. Headquartered in Cardiff with seven facilities worldwide and ~400 employees, BBI offers native and recombinant reagents that power over 5 billion annual glucose strips and 400 million lateral flow tests globally. Core products include gold nanoparticles and conjugates, enzymes, antibodies, antigens, cell culture reagents, human serum controls, and stabilizers. The company provides comprehensive contract manufacturing and development services: antibody discovery and manufacturing (up to 5g scale), custom antigen development, gold conjugation (600+ conjugations annually), and lateral flow assay design through production in ISO 13485-certified cleanrooms. BBI's expert teams troubleshoot assay performance, tailor formulations, and provide regulatory support to accelerate IVD and life sciences partners' progress from concept to commercialization.

Alife Health is an AI-powered software platform designed to modernize and optimize the in vitro fertilization (IVF) process for fertility clinics. Founded in 2020 and based in San Francisco, the company offers a configurable ecosystem of clinical decision-support tools integrated with EMR systems. Key products include Embryo Assist™ for standardized embryo cataloging and grading (reducing nurse cryo calls by ~90%), Schedule Predict for ovarian retrieval capacity optimization (reducing overcapacity days by ~65%), Success Predictor for patient engagement and outcome monitoring, and Stim Assist for personalized gonadotropin dosing. The platform leverages interpretable machine learning models trained on fertility clinic data to provide actionable insights for embryologists, lab managers, and reproductive endocrinologists. Alife's solutions are trusted by major fertility networks including US Fertility, Ovation Fertility, Shady Grove Fertility, and others. The company is HIPAA-compliant and SOC 2 Type II certified, with peer-reviewed publications in Fertility and Sterility and RBMO validating clinical efficacy.

Focalyx is a MedTech company specializing in precision diagnosis and treatment of prostate cancer through AI-driven software and minimally invasive procedural guidance. The Focalyx Fusion platform provides computer-assisted surgical planning and real-time intraoperative guidance for focal prostate therapy, enabling targeted ablation of cancerous lesions while preserving healthy prostate tissue and function. The platform combines advanced imaging analysis with GPS-like navigation to deliver office-based, outpatient prostate cancer treatment with minimal hospitalization, fast recovery, and improved preservation of urinary and sexual function. Clinical outcomes demonstrate 86% cancer-free status at 5 years with 95% urinary improvement and 88% erectile retention rates across 6,000+ procedures performed globally.

MagBio Genomics Inc. is a biotechnology company specializing in magnetic bead-based products for nucleic acid isolation and purification. Based in Gaithersburg, Maryland, the company develops comprehensive solutions for next-generation sequencing (NGS) workflows, genomic research, and clinical diagnostics. Their product portfolio includes DNA and RNA extraction kits, viral nucleic acid purification reagents, sample collection and stabilization products, post-PCR cleanup reagents, and NGS library preparation kits. MagBio's magnetic bead-based chemistry is compatible with both manual and automated laboratory platforms, supporting applications in cancer genomics, non-invasive prenatal testing (NIPT), viral diagnostics, and long-read sequencing. The company also provides OEM and custom solution development, along with distribution partnerships for life sciences research and clinical laboratories.

Veracyte is a global molecular diagnostics company specializing in genomic testing for cancer diagnosis, risk stratification, and treatment guidance. Founded in 2006 and headquartered in South San Francisco with operations in Austin, Texas, and Haifa, Israel, the company has impacted over 800,000 patients through its evidence-based portfolio of gene expression and genomic sequencing classifiers. Veracyte's core platform integrates transcriptomics, genomics, AI-assisted bioinformatics, and clinical outcome data to deliver actionable insights for thyroid, prostate, breast, bladder, and lung cancers. Key validated tests include Afirma (thyroid nodule classification), Decipher (prostate and bladder genomic assessment), and Prosigna (breast cancer risk of recurrence). The company's diagnostic innovation engine supports both LDT laboratory developed tests and collaborative R&D with biopharmaceutical partners, backed by >600 peer-reviewed publications and >35 prospective clinical trials.

Radiological Imaging Technology is an industry-leading manufacturer of quality assurance software solutions for medical physics and radiation therapy. With over 30 years of expertise, RIT provides comprehensive QA software for linear accelerators (TG-142), specialized routines for TomoTherapy (TG-148) and CyberKnife (TG-135) systems, and automated phantom analysis for diagnostic imaging. The RIT Family of Products delivers patient, machine, and imaging QA capabilities to help healthcare institutions meet regulatory and accreditation guidelines. The company serves medical physicists and imaging departments both domestically and internationally, offering workflow automation, remote QA capabilities, and compliance-focused tools engineered to ensure proper adherence to established therapeutic and diagnostic physics protocols.

Materialise N.V. is a global 3D printing and personalized healthcare technology company with 35+ years of experience in additive manufacturing. The company operates two primary business divisions: Industrial and Healthcare. The Industrial division provides 3D printing services for prototyping and serial manufacturing, alongside software solutions for managing in-house 3D printing operations across manufacturing workflows. The Healthcare division offers personalized medical solutions including 3D surgical planning software, biomechanical analysis tools, custom-made implants (including PEEK and other materials for craniomaxillofacial, orthopedic, and other applications), and clinical decision-support systems for healthcare professionals, medical device manufacturers, and academic institutions. Materialise develops software platforms for 3D modeling, image segmentation, surgical simulation, and pre-operative planning, with clinical applications spanning craniomaxillofacial surgery, orthopedics, and general surgical planning. The company serves hospitals, surgery centers, device manufacturers, and industrial customers globally. Products emphasize mass personalization, sustainability in manufacturing, and clinically validated outcomes. Materialise maintains ISO 13485 and quality management certifications relevant to medical device manufacturing and provides software and hardware solutions for personalized healthcare engineering.

InnovaQuartz LLC is a specialized manufacturer of laser fiber optics devices for endourology and surgical applications, headquartered in Phoenix, Arizona. With nearly 25 years of industry leadership, IQ designs and manufactures advanced laser fibers, connectors, and related optical components that set performance standards for urological procedures including laser lithotripsy (URS) and benign prostatic hyperplasia (BPH) treatment. The company pioneered numerous surgical innovations including the first tapered hermetically-fused laser connector (BlackHole™), shaped-output lithotripsy fibers, water-cooled side-fire fibers, and laser-polished bare fiber tips. Current product portfolio includes ProFlex™ LLF surgical fibers paired with Pulsar™ HPC technology for enhanced energy collimation, ProGuard™ sapphire-tipped fibers with burn-back resistance, and the Phoenix™ BPH laser generator. IQ also serves analytical instrumentation and optics industries with fused quartz and silica-based components. The company maintains extensive patent protections across its technology platforms and operates under ISO quality management systems.

Cell Projects Limited is a UK-based molecular biology product designer and manufacturer serving life sciences research, medical diagnostics, and forensics markets since 2002. The company specializes in Electroporation, PCR, and qPCR kits manufactured to superior performance standards. Under the Isohelix brand, Cell Projects manufactures DNA/RNA collection systems from buccal and saliva samples, along with DNA stabilization and isolation kits that integrate into downstream molecular workflows. ISO 9001:2015 and ISO 13485:2016 certified, the company offers a complete design-to-manufacturing contract service for prototyping through final production. Cell Projects provides custom OEM development, clinical diagnostic project support, and collaborative research partnerships with leading universities. The company manufactures consumable plastics for PCR, electroporation, and sample storage applications.

eKare Inc. is a digital health software company providing an integrated platform for advanced wound care management and clinical research. The company offers inSight, a CE-marked, FDA-registered wound measurement device that uses computer vision technology to capture accurate wound dimensions without reference markers. The platform combines advanced wound imaging, HIPAA and GDPR-compliant telehealth with real-time video conferencing and remote patient monitoring, clinical workflow optimization to reduce data entry burden, artificial intelligence developed by physicians for prognosis and outcome prediction, and business analytics dashboards for real-time clinical decision support. eKare serves healthcare organizations globally, from small clinics to Fortune 500 enterprises, with deployment across 56 countries. The solution integrates with major EHR systems including Epic, Cerner, and Medidata Rave via RESTful APIs and SMART on FHIR standards. Primary use cases include wound assessment standardization, patient engagement through automated alerts and secure messaging, clinical trial support with decentralized capabilities, and value-based care performance improvement. The company maintains regulatory compliance with FDA registration, CE marking, and data security certifications.

Morphle Labs Inc. is an AI-enabled health tech company specializing in digital pathology and cancer diagnostics automation. The company develops robotic whole slide scanners, robotic microtomes, and intelligent image management systems designed to enhance pathology lab workflows. Their product portfolio addresses tissue preparation, high-throughput slide scanning, AI-driven image analysis, and digital archiving. The MorphoLens scanner family (240, 6, 1 variants) and HemoLens platform serve anatomical pathology, dermatopathology, hematology, and cytology applications. Morphle's solutions enable telepathology, reduce turnaround time, improve diagnostic accuracy, and support research institutions and cancer hospitals globally. The company holds 25+ patents and emphasizes superior image quality, LIS integration, and compact data storage formats.

Geometric Medical Animation is a high-end 3D medical and scientific animation studio specializing in dynamic digital media content for the pharmaceutical, biotech, and medical device industries. The company delivers scientifically accurate mechanism-of-action (MoA) animations, custom medical illustrations, interactive digital experiences including VR/AR applications, and comprehensive digital content strategy services. With over 50 years combined experience, the team produces award-winning visual communications for healthcare marketing campaigns, medical education, and clinical communications. Services encompass 3D medical animations covering oncology, cardiovascular, rare disease, gene editing, and medical device visualization; elegant print and digital illustrations; interactive and immersive content design (mobile apps, VR, AR, mixed reality, holographic solutions); and digital booth solutions for healthcare conferences and events.

DePuy Synthes is a comprehensive orthopedic medical device manufacturer offering one of the world's largest portfolios of solutions for joint reconstruction, trauma, spine, sports medicine, craniomaxillofacial surgery, and extremities. The company specializes in orthopedic implants, surgical instruments, and digital surgery platforms designed to optimize clinical outcomes, surgeon performance, and healthcare provider efficiency. DePuy Synthes serves millions of patients globally through innovative products spanning primary and revision joint replacements, trauma fixation systems, spinal instrumentation, sports medicine solutions, and enabling digital technologies. The VELYS™ Digital Surgery portfolio represents the company's commitment to next-generation surgical capabilities. With a focus on the complete continuum of orthopedic care—from initial diagnosis through rehabilitation—DePuy Synthes combines deep surgical expertise, clinical evidence, and technological innovation to advance patient outcomes and restore mobility.

OrCam Technologies is an Israeli AI-powered assistive technology company founded in 2010, headquartered in Jerusalem with offices in New York, Toronto, and London. The company develops wearable and handheld devices for individuals who are blind, visually impaired, or have reading challenges. The flagship product line includes the OrCam MyEye series (wearable AI assistants that attach to eyeglass frames) and the OrCam Read series (handheld magnification and reading devices). All devices operate offline to protect user privacy and feature real-time text recognition, face identification, product recognition, and contextual AI assistance. OrCam serves tens of thousands of users across 50 countries in 25 languages. The company has received significant recognition, including TIME Magazine's Best Inventions of 2019, and maintains partnerships with rehabilitation agencies and distributors worldwide. Products are designed with emphasis on user independence, seamless software updates via mobile apps, and dedicated community support.

CTK Biotech, Inc. is a California-based biotechnology company specializing in the development and manufacturing of innovative point-of-care (POC) diagnostic test kits and immunodiagnostic tools for the global in vitro diagnostics (IVD) community. Founded in 1997, CTK manufactures portable, easy-to-use rapid diagnostic tests that enable quick and accurate disease diagnosis in clinical, remote, and underserved settings. The company maintains in-house production of recombinant antigens and antibodies, ensuring product quality and compliance with U.S. cGMP standards and WHO approval. CTK's product portfolio includes rapid tests for influenza A/B, H. pylori, syphilis, dengue, RSV, and HIV, with multiple products achieving CE-IVDR marking. As a wholly-owned affiliate of SSI Diagnostica A/S Group, CTK employs approximately 228 personnel and generates ~$28.2M in annual revenue, serving B2B diagnostics customers worldwide.

Foundation Medicine is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) and companion diagnostic testing for advanced cancer patients. The company develops and commercializes FDA-approved next-generation sequencing (NGS) based in vitro diagnostic tests, including FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based, circulating cell-free DNA). FoundationOne CDx analyzes 324 genes plus genomic signatures from formalin-fixed, paraffin-embedded (FFPE) tissue samples. FoundationOne Liquid CDx analyzes 324 genes using plasma specimens, reporting short variants in 311 genes, rearrangements in 8 genes, and copy number alterations in 3 genes. Foundation Medicine also offers FoundationOne Heme testing and IHC (immunohistochemistry) services. The company serves three core markets: healthcare providers and oncologists seeking biomarker-driven treatment selection; biopharmaceutical and research partners requiring companion diagnostic development, clinical trial support, and regulatory expertise across the drug development lifecycle; and patients seeking personalized cancer treatment guidance. Foundation Medicine operates a global laboratory with comprehensive EMR integration capabilities and provides decision support services and educational resources to clinicians. The company has delivered over 1.5 million genomic profiling reports and holds more than 50% of all approved US companion diagnostic indications for NGS testing. Services span discovery and translational research, clinical development and CDx strategy, and access and commercialization support. The company is FDA-regulated and maintains rigorous quality standards for molecular diagnostics.

Silver Lake Research Corporation develops, manufactures, and markets rapid point-of-care diagnostic test kits with proprietary EAP™-derived monoclonal antibodies. Founded in 1992, the company specializes in lateral flow immunoassays that deliver laboratory-grade accuracy and sensitivity in minutes at the point of care. The company operates an ISO 13485-compliant, FDA-registered US manufacturing facility—one of the largest independent automated production lines for lateral flow tests—enabling high-volume production of both proprietary products and contract-manufactured diagnostics. Key product lines include HemoTypeSC (hemoglobin phenotyping for sickle cell disease screening), WaterSafe (drinking water quality testing), and RapidBac (rapid urinary tract infection detection requiring no instrumentation). The company has marketed 150+ products and produced over 15 million test strips globally. Services include custom immunoassay development, bespoke assays for specific instruments, and private-label manufacturing. Silver Lake Research serves clinical laboratories, point-of-care testing environments, and contract manufacturing customers. The company emphasizes tangible innovation in antibody development and manufacturing partnerships, positioning itself as a turnkey solution provider for rapid diagnostic platforms.

Balchem Corporation is a specialty ingredients company founded in 1967, operating three business segments: Human Nutrition & Health (HNH), Animal Nutrition & Health (ANH), and Specialty Products. The HNH segment develops science-based nutritional ingredients including chelated minerals, vitamin K2, methylsulfonylmethane, and choline formulations targeting cognitive function and bone health. The ANH segment provides choline chloride and encapsulated nutrients for ruminants, monogastrics, and companion animals, leveraging proprietary encapsulation and spray-drying technologies. The Specialty Products segment includes Performance Gases for medical device sterilization and packaging applications, plus Metalosate® chelated minerals for agricultural markets. Balchem operates eight Innovation Centers globally and emphasizes custom ingredient development, bioavailability enhancement, and R&D-driven product innovation across human health, animal nutrition, and food production markets.

Koh Young Technology is a global leader in 3D measurement-based inspection solutions for electronics manufacturing, founded in 2002 with over 25,000 systems installed worldwide. The company specializes in advanced AI-driven Solder Paste Inspection (SPI), Automated Optical Inspection (AOI), and smart factory solutions that enhance production quality and efficiency. Koh Young's portfolio includes Dispense Process Inspection (DPI), Automated Pin Inspection (API), and Semiconductor Metrology systems that leverage cutting-edge artificial intelligence, machine learning, and deep learning technologies. The company serves electronics, automotive, aerospace, and medical device manufacturing sectors. Koh Young America, the North American division headquartered in Duluth, Georgia, is committed to continuous R&D and innovation, offering comprehensive customer support and training to ensure optimal performance of inspection and measurement solutions across global manufacturing operations.

RTsafe is a medical technology company specializing in quality assurance solutions for radiation oncology and stereotactic radiosurgery. The company develops patient-specific anatomical phantoms using advanced 3D printing technology based on patient CT scans to enable precise dosimetry verification and pretreatment quality assurance. RTsafe's flagship product, the FDA-cleared PseudoPatient®, replicates individual patient anatomy for accurate dose measurement and treatment planning validation. The company also offers the Prime Phantom for linear accelerator quality assurance, the SBRT Phantom for abdominal stereotactic body radiotherapy planning, customized phantom services, and remote dosimetry audit services. RTsafe's solutions support radiation oncologists, medical physicists, and treatment centers globally in achieving minimum-achievable-risk radiotherapy through rigorous end-to-end treatment chain validation.

SkinSAFE is a digital health platform developed in partnership with the Mayo Clinic that provides AI-powered ingredient-based product recommendations for beauty, skincare, household, and personal care products. The platform uses clinical skin testing and dermatological expertise to analyze thousands of products for their propensity to cause skin sensitivities and allergic reactions. Users receive customized product safety ratings and recommendations based on their unique skin profile, with specialized certifications for sensitive skin conditions (SkinSAFE 100, Baby SAFE, Teen SAFE, Eyelid SAFE, Lip SAFE). SkinSAFE works with CPG brands for product certifications, licensing, and digital marketing to enable safer consumer product selection.

623 Medical is a medical technology company specializing in nüm®, a sterile, single-patient-use topical anesthetic spray designed to reduce pain and anxiety associated with needle-related procedures. The fast-acting vapocoolant spray provides rapid numbing to the skin prior to vaccinations, blood draws, IV starts, injections, port access, biopsies, and minor surgical procedures. nüm eliminates cross-contamination risk through single-patient use and sterility assurance, while offering immediate onset without messy creams or loud devices. The product is particularly valuable for pediatric patients and adults with injection phobias, improving procedural comfort and patient satisfaction across healthcare settings.

Palarum is a healthcare technology company specializing in wearable IoT solutions for patient safety, fall prevention, and mobility monitoring in acute and post-acute care settings. The company develops smart textile-based devices, most notably the PUP SmartSocks™, which utilize eTextile and IoT technologies to deliver real-time alerts when fall-risk patients attempt to ambulate unassisted. Clinical trials demonstrate a 73% reduction in patient falls and 40% reduction in false alarms compared to CMS baseline metrics. Beyond fall prevention, Palarum offers mobility tracking, eRounding capabilities, and data analytics platforms designed for hospitals, rehabilitation facilities, and long-term care environments. The company also markets the SmartBadge, an emergency preparedness and staff safety solution for educational institutions. Products are developed with clinical input and have earned Nurse Approved Certification, positioning Palarum as a clinically validated player in the patient safety technology space.

Nuvo Cares is a healthcare company headquartered in Aventura, Florida, specializing in remote pregnancy monitoring and maternal-fetal health management. Founded in 2007 and publicly traded on NASDAQ since 2024, the company offers INVU by Nuvo™, the first FDA-cleared self-administered remote pregnancy monitoring system. The platform combines wearable sensors with a mobile application to enable physician-prescribed remote non-stress testing and continuous monitoring of fetal heart rate, maternal heart rate, and uterine contractions from home. The system processes vital health signals via cloud-based technology using advanced ECG and PCG sensors integrated with artificial intelligence and machine learning algorithms. INVU serves pregnant mothers, clinicians, and healthcare payers, addressing access barriers in prenatal care and improving maternal-fetal health outcomes. The company's clinical validation includes publications in the American Journal of Obstetrics and Gynecology (AJOG) demonstrating real-world effectiveness in high-risk pregnancies.

FIGUR8, Inc. develops FDA-registered musculoskeletal (MSK) assessment technology that replaces subjective measurement tools with objective, lab-grade biomechanics data. The company's flagship platform, the bioMotion Assessment Platform (bMAP), combines on-body wearable sensors with cloud-based analytics to provide precise movement analysis and functional capacity assessments. FIGUR8 serves physical therapists, orthopedic surgeons, chiropractors, occupational health clinics, workers' compensation payers, and sports medicine practitioners. The platform captures over one million data points during dynamic functional movement testing, offering quantitative metrics for injury assessment, recovery monitoring, and return-to-work determination. Use cases include workers' compensation claim management, surgical candidacy evaluation, post-injury rehabilitation tracking, and athletic performance assessment. FIGUR8 is particularly positioned for workers' compensation and occupational health markets, where objective MSK data reduces claim duration and improves outcomes. The company emphasizes clinical training and provider enablement through didactic courses and onsite support. Regulatory status includes FDA registration; the site references compliance with clinical standards and the APTA Digital Transparency Pledge. The technology addresses a significant clinical gap by providing consistent, repeatable objective metrics superior to manual muscle testing and traditional subjective clinical assessments.

Hukui Biotechnology Co., Ltd. is a Contract Development and Manufacturing Organization (CDMO) established in 2013, specializing in electronic and medical device design, engineering, and manufacturing. Headquartered in Taipei, Taiwan, with GMP-certified production facilities in Zhubei, Taiwan and Chongqing, China, plus a U.S. business office in San Jose, California, Hukui leverages deep semiconductor and electronics industry expertise to serve medtech companies globally. The company offers three core solution areas: Medical AI Devices & Senior Care (telemedicine and AI-driven diagnostics), Medical Images & Endoscopy (ultrasound and endoscopic systems), and Point-of-Care Technologies (handheld diagnostic solutions). Hukui provides comprehensive services including design engineering, product development, small to large-scale manufacturing, and global regulatory affairs registration across FDA (U.S.), TFDA (Taiwan), and NMPA (China) jurisdictions. Manufacturing capabilities include regular working rooms, cleanrooms (Class 10,000 and Class 100,000), dedicated QC labs, and warehousing. The company is positioned as a partner for transforming groundbreaking technologies into fully engineered medical solutions, with emphasis on meticulous manufacturing processes and punctual delivery. Hukui participates in major industry exhibitions including MEDICA, MD&M, and regional trade shows.

Polhemus is a global leader in 6DOF motion tracking technology with over 50 years of industry expertise. The company manufactures ultra-low latency, high-performance motion tracking sensors and systems used extensively in healthcare, medical training and simulation, military applications, and research. Their product portfolio includes wireless motion tracking systems, head tracking solutions, high-fidelity hand and finger tracking (notably for surgical simulation), embeddable sensors for catheter and surgical instrument integration, and 3D laser scanning technology. Polhemus sensors are designed for integration into medical devices, surgical training mannequins, and simulation environments. The company is recognized as a preferred supplier for surgical training systems, military helmet tracking, and precision motion capture for healthcare applications. Their technology enables tracking of fine motor movements critical for surgical training, including hand-surgeon-level fidelity. Products are fully embeddable and can operate within medical devices, under protective gloves, and in constrained clinical environments. The company serves hospital training programs, military organizations, research institutions, and medical device manufacturers requiring precise motion tracking capabilities.

Boston Micro Fabrication (BMF) is a precision micro-manufacturing company specializing in ultra-high-resolution 3D printing using Projection Micro Stereolithography (PµSL) technology. The company manufactures micro-precision parts with resolutions down to 2µm and tolerances of ±10µm (±0.025mm) for medical devices, microfluidics, electronics, optical systems, and aerospace applications. BMF's core product line includes the microArch series of 3D printing platforms (microArch S150, S240, S350, P150), which deliver industrial-grade micro-precision manufacturing capabilities in compact, desktop-scale systems. The company produces custom micro-components including endoscope shells, microfluidic chips with integrated channels as small as 400µm, electronic connectors with features down to 140µm, and chip array sockets with micro-holes at 50µm spacing. BMF recently launched BMF Clear, an optically transparent photopolymer resin with >90% light transmittance for applications requiring optical transparency at micron scales. The company serves contract manufacturing and R&D environments across medical device, electronics, microfluidics, and precision engineering sectors. Customer base includes major OEMs and contract manufacturers such as TE Connectivity, Ambu, Pristine Surgical, and research institutions. BMF enables rapid prototyping and low-volume production with 1–2 day turnaround versus traditional micro-injection molding (1–2 months), eliminating expensive tooling costs while maintaining dimensional accuracy comparable to molded components. Manufacturing capabilities span open material ecosystem support and custom benchmark part development. Regulatory and quality credentials not explicitly stated on homepage; medical device focus suggests ISO 13485 and 510(k) compliance typical for the sector.

Intuitive Surgical, Inc. is a global leader in robotic-assisted surgical systems and digital health solutions. The company manufactures the da Vinci family of robotic surgery platforms, which enable minimally invasive surgical procedures across multiple specialties including general surgery, urology, gynecology, cardiothoracic, and orthopedics. Core product lines include the da Vinci 5 (advanced integrated robotic platform with surgeon console and patient cart), the da Vinci SP (single-port robotic system for new surgical approaches), and the Ion robotic bronchoscopy system for lung cancer diagnosis and biopsy. Intuitive also manufactures da Vinci instruments and accessories designed for precision and ergonomic control. Beyond hardware, the company provides digital solutions including My Intuitive (data analytics and insights platform for surgical teams) and SimNow (surgeon training and simulation software). The company operates a global infrastructure with expanded direct operations in Europe and provides 24/7 service and support. Intuitive's systems are used in hospitals worldwide for minimally invasive surgery, and the company has established itself as the market leader in robotic-assisted surgical technology since its founding in 1995. The platform emphasizes surgeon autonomy, precision, and patient outcomes through advanced visualization and control systems.

Geneoscopy Inc. is a St. Louis-based life sciences company specializing in noninvasive molecular diagnostics for gastrointestinal diseases. The company has developed a proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform enabling precision medicine approaches to colorectal cancer screening and inflammatory bowel disease diagnosis. ColoSense, its FDA-approved flagship product, is an at-home stool test for colorectal cancer screening in average-risk individuals aged 45+, utilizing Bio-Rad's Droplet Digital PCR technology to achieve high sensitivity for cancer and advanced adenomas detection. Operating from a CLIA-certified laboratory with ~50-55 employees, Geneoscopy addresses critical gaps in colorectal cancer screening accessibility by reducing procedural barriers associated with colonoscopy. The company is expanding its diagnostic portfolio for IBD management and collaborates with major partners including Bio-Rad Laboratories and Labcorp to enhance test distribution and promote health equity in cancer prevention.

IUL SA, founded in 1987, designs, manufactures, and markets microbiological control instruments and diagnostic devices serving laboratory, food safety, pharmaceutical, and environmental monitoring sectors. The company operates three primary divisions: IUL Micro (classical microbiology lab automation and consumables), MedIUL (lateral flow test readers for in-vitro diagnostics), and OEM (original equipment manufacturer services). Core product lines include automated colony counting and spiraling systems, air samplers (EN 17141/2020 compliant), and lateral flow reader platforms. Key innovations include the SphereFlash® AI colony counting software (AI-powered automated image analysis), iPeak® Europium and iPeak® Plus lateral flow readers for fluorescence and colorimetric assays, the Eddy Jet 2W spiral plater for rapid culture plating, and Spin Air high-biocollection efficiency samplers for environmental microbiology. All instruments are designed with original patents and engineered for reduced turnaround time in microbiology testing workflows. The company recently expanded internationally with U.S. headquarters established in 2025 and German operations (IUL GmbH), indicating growth in North American and European markets. Serves pharmaceutical QA/QC, food safety, clinical microbiology, and environmental monitoring laboratories.

Lady Technologies is a women's health company developing a proprietary vaginal health platform centered on cervical mucus biomarker analysis. Their flagship product, kegg, is an intravaginal device that measures cervical mucus changes to identify fertile windows, provide pelvic floor training, and deliver actionable health insights. The platform currently focuses on fertility tracking and conception support, with clinical applications extending to non-hormonal contraception, infection detection, and pelvic floor health monitoring. kegg has supported over 50,000 women on their fertility journeys. The company emphasizes a data-driven, personalized approach to women's health by collecting and analyzing the largest known dataset on cervical mucus patterns. Lady Technologies is building a broader vaginal health ecosystem with potential for expanded diagnostic and therapeutic applications beyond fertility.

Tally Surgical, Inc. designs and manufactures a proprietary RFID-based retained surgical sponge detection system. The company's flagship product uses unique RFID technology embedded in surgical sponges to prevent retained foreign objects (RFOs), one of the most common adverse events in surgery. The system operates at up to 900+ scans per second and includes a proprietary FIND MODE feature to rapidly locate missing sponges in the operating room. Tally's solution addresses a critical patient safety concern: retained surgical sponges affect an estimated 92% of patients with permanent or temporary injury and carry an average indemnity payout of $473,000 per incident, plus corrective surgery costs averaging $77,512. The company positions its cost-competitive offering as an alternative to manual counting and existing technologies. Tally Surgical serves hospital operating rooms and surgical centers seeking to reduce never-events and associated liability while improving clinical outcomes. The company is headquartered in Aliso Viejo, California and is led by industry veterans who previously developed first-generation retained sponge prevention products.

Menarini Silicon Biosystems is a clinical laboratory and diagnostic services company specializing in non-invasive biomarker detection and cell-based assays for oncology and precision medicine applications. The company is part of the Menarini Group and operates as a CLIA-certified laboratory offering proprietary circulating tumor cell (CTC) detection platforms and phenotyping services. Primary product is CELLSEARCH®, the first and only FDA-cleared actionable test for detecting and enumerating circulating tumor cells in patients with metastatic breast, prostate, and colorectal cancer, with clinical utility demonstrated in guiding therapeutic strategy and monitoring disease progression. The company also offers CELLSEARCH® Circulating Multiple Myeloma Cell Test for minimally invasive serological monitoring via blood draw, and emerging cell-based non-invasive prenatal testing (NIPT) technology for detection of fetal genomic abnormalities. Services include biomarker phenotyping, clinical laboratory testing for biopharma clinical trials, and comprehensive research support. The company serves oncology centers, biopharma sponsors, and healthcare systems requiring standardized, reliable CTC enumeration and biomarker profiling for patient stratification, treatment monitoring, and drug development. Quality and regulatory compliance are core operational principles.

Viro Research™ manufactures high-quality biological products and reagents for research and in vitro diagnosis of human viral infections, with specialized focus on VZV (varicella-zoster virus) and HSV (herpes simplex virus) detection. The company develops fluorescent antibody-based diagnostic tests that enable rapid, accurate patient diagnosis and guide treatment pathways for physicians and clinical laboratories. Products utilize proprietary monoclonal antibody technology to deliver enhanced diagnostic sensitivity and specificity, particularly for detection of chickenpox, shingles (herpes zoster), and other viral pathogens in clinical specimens and cell culture.

Onyx Healthcare USA is an FDA-registered, ISO 13485-certified medical technology company headquartered in Orange, California, with manufacturing operations in New Taipei City, Taiwan. With over 20 years of specialized experience, Onyx designs and manufactures medical-grade computing solutions and AI-ready platforms for healthcare providers, medical device manufacturers, and integrators. The company offers comprehensive OEM/ODM services, including custom medical device design, rapid prototyping, and production of UL 60601-1 certified computing systems. Product portfolio encompasses medical PCs, slim medical panel PCs, all-in-one workstations, bedside terminals, mobile computing carts with hot-swap batteries, medical tablets, medical displays, single-board computers, and accessories. Onyx specializes in AI-accelerated edge computing platforms featuring NVIDIA and Intel processors, supporting real-time medical imaging, surgical applications, and clinical inference. Additional offerings include hospital IT services, telemedicine solutions, mobile nursing stations, patient engagement systems, and the proprietary Orion Hospital IT Management Software. The company serves North American and Latin American healthcare markets with a focus on quality, regulatory compliance, and extended product longevity.

Nerbio Medical Software Platforms manufactures and delivers the iTOF®, the world's first and only FDA-cleared, wireless, app-controlled quantitative train-of-four (TOF) neuromuscular monitoring device. The iTOF connects to smartphones and tablets to provide real-time, quantitative neuromuscular assessments in perioperative settings without requiring bulky standalone equipment or significant capital investment. The platform integrates advanced AI assistance to help clinicians accurately guide neuromuscular blocking agent dosing and determine optimal post-operative recovery timing. Delivered as a Medical Device as a Service subscription model, iTOF operates at minimal daily cost (approximately $1/day) with full replacement warranty and no disposable costs. Clinical data demonstrates 10% improvement in operating room throughput, 15–30% reduction in neuromuscular blocking agent use, and significant reduction in post-operative residual blockade complications. The device is portable, battery-operated, hands-free, and compatible with both iOS and Android platforms. Nerbio is building a comprehensive platform of mobile, AI-powered monitoring solutions for perioperative and critical care environments.

Dedicated Computing is a Wisconsin-based original design manufacturer (ODM) founded in 1978, specializing in the design, development, and manufacturing of embedded computing systems, hardware, and software platforms for OEMs in mission-critical industries. The company delivers high-performance, reliable, and customizable solutions for healthcare, training and simulation, and industrial automation. Dedicated Computing manufactures complete, certified, integrated systems optimized for OEM applications, including custom computing platforms, rack-scale integration, and comprehensive lifecycle management services. The company powers essential medical devices and professional training simulators, and partners with leading technology firms including Intel, NVIDIA, and AMD. Its DC Digital Services offering includes proactive system lifecycle management, component obsolescence planning, embedded OS transitions, remote diagnostics, and 24/7 support services. Dedicated Computing emphasizes quality, reliability, and compliance in high-stakes environments.

Sinochips Diagnostics is a CLIA & CAP-accredited clinical laboratory specializing in advanced molecular testing for precision medicine and diagnostics. The company offers pharmacogenomics testing (DNA-based medication optimization), infectious disease panels (respiratory pathogens, UTI), and biomarker analysis with rapid turnaround times. Services include multiplex PCR panels, serology testing, and diagnostic rRT-PCR assays, primarily serving healthcare providers, clinics, and hospitals. Sinochips combines state-of-the-art molecular technology with streamlined sample collection, processing, and secure online result portals to enable data-driven clinical decision-making.

Vycor Medical, Inc. operates two distinct business units specializing in neurosurgical and neurotherapeutic solutions. The primary division designs and manufactures neurosurgical medical devices, with the ViewSite Brain Access System (VBAS) as the flagship product—a minimally invasive neurosurgical device that improves access to brain lesions while reducing tissue damage. Clinical evidence from over 50 studies demonstrates VBAS results in reduced brain tissue trauma, minimized invasiveness, improved surgical visibility, and shortened operating and recovery times. The company's secondary business unit, NovaVision, develops non-invasive, computer-based vision rehabilitation therapies for patients with vision loss resulting from neurological trauma such as stroke. NovaVision Visual Restoration Therapy (VRT) is the only FDA-cleared therapy for vision rehabilitation following neurological brain damage; it is complemented by the NeuroEyeCoach program, which trains patients to make improved eye movements to enhance visual field detection. Vycor Medical serves neurosurgeons, neurologists, rehabilitation specialists, and vision care providers across hospital and outpatient settings. The company holds FDA regulatory clearance for its therapeutic products and demonstrates commitment to clinical validation and evidence-based outcomes.

JOGO Health is a digital therapeutics company specializing in FDA-registered Class II EMG biofeedback systems for pain and neuromuscular disorder management. The platform integrates wearable sensors with advanced AI to leverage neuroplasticity, delivering non-invasive, medication-free virtual rehabilitation. Founded on research by Dr. Joseph Brudny (NYU) and Dr. Gordon Silverman (Rockefeller University), JOGO combines Electromyography biofeedback, Pain Neuroscience Education, Pain Reprocessing Therapy, and physical therapy. Clinical trials at Brigham and Women's Hospital (Harvard) and Mayo Clinic demonstrated superior outcomes versus opioids for chronic pain and superiority over standard care for neuromuscular disorders. The platform enables hybrid or fully virtual tele-rehabilitation, allowing home-based therapy. Medicare and major commercial payers cover JOGO for migraine, tension-type headache, cancer pain, urinary incontinence, pelvic pain, fecal incontinence, chronic constipation, stroke recovery, and neurorehabilitation. Indicated conditions include Parkinson's, Essential Tremor, cerebral palsy, Bell's palsy, spinal cord injury, and multiple sclerosis.

Enlight Medical Technologies is a global medical technology company headquartered in Boston, Massachusetts, with research and development centers and manufacturing facilities in Boston, San Francisco, Shanghai, Beijing, and Shenzhen. The company specializes in interventional medical devices for structural heart disease, vascular intervention, and neuromodulation products. The company's core therapeutic areas include: (1) valve intervention—addressing mitral regurgitation and other valvular pathologies through catheterization-based approaches; (2) aortic and peripheral intervention—treating aortic dissection and peripheral vascular disease; (3) neuromodulation—using electrode stimulation for Parkinson's disease, epilepsy, chronic pain, and urinary incontinence; and (4) brain-computer interface (BCI) technology for neurological applications and functional enhancement. The company also develops life science and diagnostic platforms, including proteomic analysis tools aligned with the Human Protein Atlas initiative. Enlight Medical maintains GMP-certified manufacturing facilities and operates across both passive and active device platforms with AI imaging capabilities. The company holds multiple medical device licenses in China and has multiple advanced clinical-stage or submitted products. Research and development teams have 15+ years of medical device engineering and production management experience. The company was founded in Boston and has expanded significantly in China, serving structural heart disease and neuromodulation markets. As of 2023, a spinoff entity (Yinghe Brain Science) completed a Series A funding round focused on next-generation neuromodulation and BCI technology development.

BioLegend is a biomedical research company specializing in the development and manufacturing of research reagents and antibodies for scientific investigations. The company operates a modern manufacturing facility in San Diego, California, and offers a comprehensive portfolio including monoclonal and polyclonal antibodies, immunoassay solutions, recombinant proteins, magnetic cell separation products, and single-cell proteogenomics reagents. BioLegend serves research institutions, pharmaceutical companies, and clinical laboratories across multiple therapeutic areas including neuroscience, oncology, immunology, stem cell research, and clinical diagnostics. The company has acquired the Covance antibody product portfolio to strengthen its neuroscience offerings and collaborates with leading research organizations such as The Michael J. Fox Foundation for Parkinson's Research and Illumina. BioLegend provides IVD (in vitro diagnostic) reagents and ASR (Analyte Specific Reagent) products for immunohistochemistry, immunophenotyping, and flow cytometry applications. The company emphasizes quality manufacturing, expert technical support, and custom product development services to support precision medicine, oncology, and biomedical discovery.

Cognoa is a pediatric behavioral health company developing AI-powered digital diagnostics and therapeutics for early childhood developmental conditions, with a focus on autism spectrum disorder. The company's flagship product, Canvas Dx™, is the first FDA-authorized digital diagnostic aid for autism in children aged 1.5 to 6 years, enabling remote evaluation and rapid diagnosis within days rather than months or years. Canvas Dx combines analysis of parent questionnaires and child behavior video to provide objective, data-driven diagnostic support that reduces diagnostic delays, healthcare costs, and disparities in care access—particularly for underserved and minority populations. The platform has achieved reimbursement coverage through Highmark Insurance and multiple state Medicaid programs. Beyond autism diagnostics, Cognoa is expanding its AI platform to address other pediatric behavioral health conditions including ADHD and anxiety, with a commitment to equitable, early intervention in developmental health assessment and treatment.

3D-Side is a software and patient-specific medical device company specializing in AI-powered 3D preoperative planning and personalized healthcare solutions. The company operates a cloud-based platform called Customize, which integrates case management, communication, quality management, and full traceability for patient-specific medical device production. The platform supports three main product lines: 3D-Arthro (arthroplasty planning and patient-specific instrumentation for shoulder and ankle, with FDA 510(k) clearance), 3D-Cut (bone tumor resection and corrective osteotomy cutting guides), and 3D-Skull (cranioplasty solutions with AI-based segmentation and custom cranial implant design). 3D-Side targets neurosurgeons, orthopedic surgeons, arthroplasty implant manufacturers, and patient-specific device manufacturers. The platform covers the entire surgical journey from preoperative planning through intraoperative execution to postoperative surveillance. The Customize platform features AI automation for segmentation, communication, document generation, and case management, enabling scalable production of patient-specific devices. The company designs turnkey solutions tailored to customer implant philosophy and surgical approach, with rapid design and manufacturing capabilities. 3D-Skull specializes in cranioplasty molds for intraoperative PMMA implant creation, reducing lead times and manufacturing costs.

Medical Predictive Science Corporation (MPSC) develops the HeRO (Heart Rate Characteristics) System, an FDA-cleared predictive monitoring platform for neonatal intensive care. HeRO uses proprietary algorithms to detect subtle irregularities in heart rate variability that precede patient deterioration by hours to days, providing early warning for sepsis, necrotizing enterocolitis (NEC), urinary tract infections, meningitis, respiratory decompensation, brain pathology, and mortality risk. The technology analyzes cytokine-driven changes in autonomic nervous system response during early infection and inflammatory events, generating hourly risk scores for infection in the subsequent 24 hours. Clinical evidence from the largest randomized controlled trial in neonatology (3,003 very low birthweight infants) demonstrated a 22% reduction in overall mortality and 40% reduction in mortality among infected patients, with average diagnostic timing improvement of 18+ hours—enabling earlier antibiotic intervention before systemic progression. HeRO operates as a standalone bedside monitor or embedded module within compatible central monitoring systems.

Neuro Rehab Recovery Technologies is a clinical solutions developer and distributor specializing in advanced neurorehabilitation equipment and systems. The company operates across North America, with primary headquarters in the USA and distribution presence in Canada, Mexico, Bolivia, Colombia, and Costa Rica. The organization markets itself as clinician-owned and operated, providing a comprehensive portfolio of technologies for neurological injuries and diseases including stroke, cerebral palsy, spinal cord injury, and traumatic brain injury. Product portfolio includes robotic rehabilitation systems (exoskeletons: Keeogo, ExoAtlet EA2), hand rehabilitation devices (SYREBO hand robots, G1 robotic glove, H2 system), functional electrical stimulation systems (G4 FES Foot Drop System), active-passive therapy systems (MOTOmed series for upper and lower extremity), gait training treadmills (AeroRunner anti-gravity system), mirror therapy systems (Syrebo Smart Rehabilitation Mirror), dynamic arm support systems, and VR-based balance assessment and training platforms (UprightVR). The company also distributes the Neuro20 Smart stimulation device and percussive massage equipment. Neuro Rehab Recovery positions itself as a clinical education and training partner rather than a treatment clinic, emphasizing comprehensive training, clinical support, and evidence-based outcomes. The company serves clinics, rehabilitation facilities, hospitals, and individual patients. Major institutional partners include Cleveland Clinic, NewYork-Presbyterian, NYU, CHOP, Northwell Health, and numerous orthotics and prosthetics centers. The organization distributes technologies from multiple global manufacturers and maintains an e-commerce platform for direct consumer sales. No specific FDA clearances or certifications are mentioned on the primary website content provided.

IBA Dosimetry GmbH is a medical technology company specializing in quality assurance (QA) solutions for radiation therapy, proton therapy, and diagnostic imaging. With over 50 years of experience, the company develops innovative tools and software that enable medical physicists to verify treatment accuracy, ensure patient safety, and optimize clinical workflows. Their offerings encompass independent QA solutions for photon and particle therapies, patient-specific QA systems (including the myQA MatriXX AiR wireless ionization chamber array for proton and carbon ion treatments), and customizable diagnostic imaging QA platforms. IBA Dosimetry operates globally with regional offices in Germany, the United States, China, Canada, and India, providing 24/7 expert support and training to healthcare institutions worldwide. As part of the IBA Group, known for particle accelerator technology, IBA Dosimetry combines deep clinical physics expertise with commitment to advancing cancer care and patient outcomes.

SICAT GmbH & Co. KG is a leading innovator in digital dentistry software and surgical planning solutions based in Bonn, Germany. Founded in 2004, the company specializes in 3D-based analysis and planning software, AI-driven surgical guides, and therapeutic appliances for dental practices, clinics, and laboratories worldwide. SICAT integrates diverse data sources including CBCT imaging and optical impressions to enable virtual treatment planning and execution. Core product offerings include SICAT Implant 2.0 for implantology planning, SICAT Air and OPTISLEEP for sleep apnea therapy, RAPID ACCESSGUIDE for endodontic surgical guidance, and a comprehensive Smart Subscription model providing modular software access. The platform operates as an open ecosystem compatible with all major CBCT and optical scanner systems. SICAT serves B2B dental stakeholders through cloud-based workflows, implant databases, and integrated surgical guide design leveraging AI technology.

Capitainer AB is a Swedish medtech company founded in 2013 by Professor Olof Beck from the Karolinska Institute, specializing in intelligent microsampling devices for remote blood and fluid collection. The company's proprietary microfluidic technology enables patients to collect precise volumes of whole blood, cell-separated plasma, and other fluids at home, which can be mailed to laboratories for analysis without specialized handling or trained phlebotomists. Capitainer's flagship product, the Capitainer qDBS (quantitative Dried Blood Spot), delivers volumetric accuracy equivalent to traditional pipetting while featuring an integrated success indicator and high first-time-user success rates. The company also offers automated sample handlers and solutions for clinical diagnostics, chronic disease monitoring, immunosuppressive drug sampling, infectious disease serology, and oncology screening applications. Capitainer targets healthcare providers, clinical laboratories, and diagnostic organizations seeking cost-effective, convenient alternatives to traditional venipuncture-based blood collection.